University of California, San Francisco (UCSF) is one of eighteen Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Stephen Gitelman, MD, the TrialNet team at UCSF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by Principal Investigator, Lou Philipson, MD, the TrialNet team at the University of Chicago is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of Chicago is regionally overseen by Indiana University - Riley Hospital. If you reach out to TrialNet, you may be contacted by staff from either institution. 

The University of Florida (UF) is one of eighteen Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Michael Haller, MD, the TrialNet team at UF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by David Baidal, MD, the TrialNet team at University of Miami is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Note: As a TrialNet affiliate, University of Miami is regionally overseen by University of Florida. If you reach out to TrialNet, you may be contacted by staff from either institution. 

Led by Inas Thomas, MD, the TrialNet team at University of Michigan is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of Michigan is regionally overseen by Indiana University - Riley Hospital for Children. If you reach out to TrialNet, you may be contacted by staff from either institution. 

University of Minnesota is one of eighteen type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Led by Nina Jain, MD, the TrialNet team at UNC Chapel Hill is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, UNC Chapel Hill is regionally overseen by Vanderbilt Eskind Diabetes Clinic. If you reach out to TrialNet, you may be contacted by staff from either institution. 

University of Pittsburgh is one of eighteen type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Ingrid Libman, MD, PhD, the TrialNet team at University of Pittsburgh is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. Our center is located at the Children's Hospital of Pittsburgh of UPMC.

Led by Henry Rodriguez, MD, the TrialNet team at University of South Florida (USF) is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of South Florida is regionally overseen by University of Florida. If you reach out to TrialNet, you may be contacted by staff from either institution. 

Led by Kathryn Sumpter, MD, the TrialNet team at University of Tennessee/ Methodist Le Bonheur Healthcare is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Note: As a TrialNet affiliate, University of Tennessee/ Methodist Le Bonheur Healthcare is regionally overseen by Vanderbilt Eskind Diabetes Clinic. If you reach out to TrialNet, you may be contacted by staff from either institution.